NCT03161834: Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

NCT03161834
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended

Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Tissue biopsies that support the presence of both ER+ and ER- MBC in the same patient
https://ClinicalTrials.gov/show/NCT03161834

Comments are closed.

Up ↑